Literature Analysis of Adverse Drug Reactions Induced by Adalimumab
Objective To provide a reference for the rational use of adalimumab in clinical practice.Methods The Chinese and English studies with adalimumab as the primary suspected drug in the CNKI,WanFang,VIP and PubMed from the inception of each database to December 2022 were searched.The patients' basic information and adverse drug reactions(ADRs)induced by adalimumab were collected,classified and analyzed.Results A total of 283 studies were searched,and 101 were obtained after screening,involving 101 patients.Among them,there were 56 males(55.45% )and 45 females(44.55% ),aged from eight to 82 years,with an average of(45.39±17.32)years,mainly>40 to 60 years(47 cases).The number of patients from the United States was the highest(16 cases),while that from China and the United Kingdom was tied for the fourth(nine cases).The patients'primary disease was mainly Crohn's disease(22 cases,21.78% ).The ADRs mainly affecting the skin and its appendages(40 cases,39.60% ),and the most common clinical manifestation was drug eruption(14 cases,13.86% ).Most ADRs were graded as moderate(64 cases,63.37% ).Most ADRs were probably associated with adalimuma(79 cases,78.22% ).There were 21 cases of combined medication(20.79% ),including 18 cases of dual medication,two cases of triple medication and one case of quadruple medication.The most common medication course was eight weeks.A total of 73 patients was cured and improved after drug withdrawal and(or)medication treatment(including symptomatic supportive treatment,changing drug or dosage,etc.),while two patients still died after the above treatment.Conclusion Clinicians should accurately know the medication indications when using adalimumab,strictly follow the drug instructions,be familiar with the common types and occurrence time of ADRs,strengthen the ADR monitoring to ensure the medication safety.
adalimumabadverse drug reactionliterature analysismedication safetypharmaceutical care
国家科技期刊平台
NSTL
万方数据
